Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zymeworks's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zymeworks's regulatory disclosures and financial reporting.
ZYME filed a notice of proposed sale of restricted securities under Rule 144. The notice covers the planned sale of 6,832 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026 on the Nasdaq market, with an aggregate market value of 158,297.44 at the time of the notice. The filing states that 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units awarded by the issuer. The notice also indicates that 74,836,534 shares of common stock were outstanding at the time referenced.
Zymeworks Inc. insider trading notice outlines planned and recent share sales. A holder plans to sell 9,560 shares of Zymeworks common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an aggregate market value of $221,505.20, while 74,836,534 shares of common stock are outstanding. These shares relate to the vesting of 17,666 restricted stock units on 01/12/2026, with vesting noted as the form of payment. The filing also reports that Paul Andrew Moore sold 20,110 shares of common stock on 01/05/2026 for gross proceeds of $504,698.65. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about Zymeworks’ operations.
Zymeworks Inc. insider Jeffrey T L Smith has filed a notice of proposed sale of common stock under Rule 144. The filing indicates an intent to sell 9,310 shares of common stock through Morgan Stanley Wealth Management Canada on the Nasdaq, with an aggregate market value of 215,712.70. The filing notes that 74,836,534 shares of common stock were outstanding.
The securities to be sold were acquired on 01/12/2026 through the vesting of 17,666 restricted stock units granted by the issuer, with the nature of payment described as a vesting of award. During the prior three months, Smith sold 10,538 shares of common stock on 01/05/2026 for gross proceeds of 264,471.13. By signing, the seller represents that he is not aware of undisclosed material adverse information about the company.
Zymeworks Inc. insider Kenneth Galbraith has filed a Form 144 indicating an intention to sell 30,424 shares of common stock on or about 01/12/2026 through Morgan Stanley Wealth Management Canada on Nasdaq, with an aggregate market value of $704,924.08.
The filing shows that 64,000 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units from the issuer, with payment described as vesting of an award.
Over the prior three months, the same seller reported two sales of Zymeworks common stock: 47,528 shares on 12/22/2025 for gross proceeds of $1,284,311.12, and 54,343 shares on 01/05/2026 for gross proceeds of $1,363,840.84.
Zymeworks Inc. insider Mark Hollywood has filed a Form 144 notice to sell common stock. The filing covers a planned sale of 6,120 shares of common stock through Morgan Stanley Wealth Management Canada on or about 01/12/2026, with an indicated aggregate market value of $141,800.40. The class is listed on the Nasdaq, and there were 74,836,534 shares of this class outstanding.
The shares to be sold are tied to equity compensation, as 17,666 shares of common stock were acquired on 01/12/2026 through the vesting of restricted stock units granted by the issuer. The filer also reported that, during the prior three months, Mark Hollywood sold 8,911 shares of common stock on 01/05/2026 for gross proceeds of $223,638.47. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about Zymeworks’ current or prospective operations.
Zymeworks Inc. reported preliminary, unaudited cash resources of about $270.6 million as of December 31, 2025, and said that, based on current plans, it believes it can fund operations beyond 2028 assuming full execution of a $125.0 million share repurchase plan and receipt of $440.0 million in anticipated regulatory milestone payments tied to potential Ziihera approvals in GEA across the United States, Europe, Japan and China. The company also announced multiple leadership changes, including appointing Brian Cherry as a new Class II director, terminating Executive Vice President, Chief Business Officer and Chief Financial Officer Leone Patterson without cause, and naming Chair, President and CEO Kenneth Galbraith as interim Chief Financial Officer. Zymeworks promoted Mark Hollywood to Executive Vice President and Chief Operating Officer with increased salary and new equity awards, and outlined a planned transition in the Chief Medical Officer role from Jeffrey Smith, who is retiring, to Sabeen Mekan.
Zymeworks Inc. executive Patterson Leone, EVP and Chief Business & Financial Officer, reported buying common stock through the company’s employee stock purchase plan. On January 6, 2026, Leone acquired 459 shares of common stock at a price of $10.55 per share, bringing reported beneficial ownership to 459 shares held directly. The filing notes these shares were purchased under Zymeworks’ Amended and Restated Employee Stock Purchase Plan for the purchase period from July 1, 2025 through December 31, 2025, at a price equal to 85% of the closing price of the stock on July 1, 2025.
Zymeworks Inc. reported several updates. Director Scott Platshon resigned from the board effective immediately, and the company stated his resignation was not due to any disagreement over operations, policies, or practices. The company announced a strategic initiative to optimize future cash flows from Ziihera® (zanidatamab-hrii), other licensed products, and other healthcare assets. The board also authorized a $125.0 million share repurchase program for its common stock.
As part of its financial outlook, Zymeworks noted that, assuming full execution of the $125.0 million repurchase program, its existing cash resources of $299.4 million as of September 30, 2025, together with anticipated milestone payments tied to potential regulatory approvals of Ziihera in the United States, Europe, Japan and China, are expected to fund planned operations beyond 2028. Separately, the company announced the appointment of Mr. Platshon as Acting Chief Investment Officer.
Zymeworks Inc. (ZYME) announced positive topline Phase 3 results for its lead drug Ziihera® (zanidatamab-hrii). The HERIZON-GEA-01 trial evaluated Ziihera in combination with chemotherapy, with or without the PD‑1 inhibitor Tevimbra® (tislelizumab), as a first-line treatment for HER2‑positive locally advanced or metastatic gastroesophageal adenocarcinoma. This includes cancers of the stomach, gastroesophageal junction, and esophagus, an area of significant medical need. The positive topline outcome from this late‑stage study suggests Ziihera may have meaningful clinical activity in this setting, and further details are provided in the company’s November 17, 2025 press release.